InvestorsHub Logo
Followers 91
Posts 17158
Boards Moderated 0
Alias Born 09/06/2006

Re: CherryTree1 post# 149505

Thursday, 12/14/2017 10:59:45 AM

Thursday, December 14, 2017 10:59:45 AM

Post# of 687452
The same publication lists at least 2 other drugs that had already failed a P3 and are certainly not being on the market next year.

The entry right below DCVax is GALE's NeuVax. The P3 trial was halted for futility over a year ago. It is now in a couple of P2 trials.

And the previous page has Zybrestat (now called CA4P) from OXiGENE (now called Maeton). P3 failed, drug is now in a P1 combo trial with CIs.

Kind of indicates the source is not all that accurate or up-to-date.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News